Drugs and Devices

FDA approves Surfaxin to prevent respiratory distress syndrome in premature infants.

On March 6, the U.S. Food and Drug Administration (FDA) announced the approval of Surfaxin (lucinactant) for the prevention of respiratory distress syndrome in premature infants. Read more.


Related Articles:

Leave a Reply

You have to agree to the comment policy.

 

Test Your Nursing Knowledge

Answer this interactive quiz to be entered to win a gift card.

  • This field is for validation purposes and should be left unchanged.

Insights Blog

Today’s News in Nursing

Shares